Findings

What do systematic reviews say?

10 questions · 10 findings · 2 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 40%GRADE not reported 2 · 20%Very low 0 · 0%Low 0 · 0%Moderate 4 · 40%High 0 · 0%

Cetirizine 0.5 mg/kg/d vs placebo (18‐month intervention)

Pruritus · children with eczema

The review found no eligible studies for this question.

1 finding from 1 review

Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cetirizine 0.5 mg/kg/d vs placebo (18‐month intervention)

Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · children with eczema

Cetirizine 0.5 mg/kg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (18‐month intervention) (moderate certainty).

1 finding from 1 review

Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
RR 0.68 [0.46, 1.01]
1 study · 795 participants
Moderate

Cetirizine 0.5 mg/kg/d vs placebo (18‐month intervention)

Physician‐assessed changes in clinical signs · children with eczema

1 finding from 1 review

Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 795 participants
Moderate

Cetirizine 0.5 mg/kg/d vs placebo (18‐month intervention)

Secondary outcome: quality of life · children with eczema

The review found no eligible studies for this question.

1 finding from 1 review

Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cetirizine 0.5 mg/kg/d vs placebo (18‐month intervention)

Secondary outcome: clinical flare · children with eczema

1 finding from 1 review

Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 795 participants
Moderate

R‐salbutamol 0.5% topical cream vs placebo

Clearing or excellent improvement · people with discoid lupus erythematosus

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 37 participants
GRADE not reported

R‐salbutamol 0.5% topical cream vs placebo

At least 50% reduction in erythema · people with discoid lupus erythematosus

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 37 participants
GRADE not reported

R‐salbutamol 0.5% topical cream vs placebo

Quality of life measure · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

R‐salbutamol 0.5% topical cream vs placebo

Relapse · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

R‐salbutamol 0.5% topical cream vs placebo

Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 37 participants
Moderate